Individual Neurophysiological Sensory Profiles in People With and Without Neurodevelopmental Disorders (SensAUry)

April 17, 2026 updated by: University Hospital, Tours

The goal of this observational study is to evaluate intra-individual neurophysiological variability in children and adults with and without NeuroDevelopmental Disorders (NDD), for several sensory modalities and types of stimulation. The main hypotheses are:

  • NDD participants and children exhibit higher intra-individual variability than other participants
  • intra-individual neurophysiological variability is correlated to behavioral, psychological and learning profiles

Participants in this study will:

  • be recorded for EEG and other neurophysiological parameters while exposed to sensory stimulations, to quantify sensory neurophysiological variability
  • perform behavioral tests and fill out questionnaires, to establish the behavioral and psychological profile
  • train for perceptual learning, to measure learning abilities

These evaluations will be split in 3 visits spread on a maximum of 3 months, and training for learning will be done at home in between 2 visits.

Study Overview

Status

Not yet recruiting

Study Type

Observational

Enrollment (Estimated)

200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Participants will be adults between 18 and 45 years old and children between 6 and 12 years old, with or without a Neurodevelopmental Disorder.

Description

Inclusion Criteria:

  • Social security affiliation
  • Free and written informed consent from the participants (Neurotypical Adults, NDD Adults without judicial protective measures), or their tutor or legal representant(s) (other participants)
  • Age between 6 and 12 years included (Children) or between 18 and 45 years included (Adults)
  • For NDD participants: NDD diagnosis by a qualified medical professional, according to DSM-4, DSM-5, ICD-10 or ICD-11 criteria

Non-inclusion Criteria:

  • Psychotropic medication perturbing EEG recording
  • Drugs pertubing peripheral neurophysiological measures
  • Non-corrected visual or auditory troubles
  • Known neurological or psychiatric conditions (at the exclusion of NDD for NDD participants)
  • Epilepsy
  • Inclusion in another ongoing medical protocol
  • For Neurotypical participants: NDD diagnosis
  • For NDD participants: anticipated psychological or physical risk at participating, at the investigator's discretion

Exclusion Criteria:

  • Participants with no data to evaluate Outcome 1

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Neurodevelopmental Disorders Children
6-12 years old children
Neurodevelopmental Disorders Adults
18-45 years old adults
Neurotypical Children
6-12 years old children
Neurotypical Adults
18-45 years old adults

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Amplitude of central neurophysiological responses to sensory stimulations
Time Frame: Through study completion, an average of 2 months per participant
Amplitude (in micro-volts) of event-related potentials
Through study completion, an average of 2 months per participant
Latency of central neurophysiological responses to sensory stimulations
Time Frame: Through study completion, an average of 2 months per participant
Latency (in milli-seconds) of event-related potentials
Through study completion, an average of 2 months per participant
Variability of central neurophysiological responses to sensory stimulations
Time Frame: Through study completion, an average of 2 months per participant
Intra-individual variability (in percentage) of event-related potentials
Through study completion, an average of 2 months per participant

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Visual perceptual learning performance
Time Frame: Through study completion, an average of 2 months per participant
Discrimination performance (in percentage) for visual delayed-matching to sample task
Through study completion, an average of 2 months per participant
Auditory perceptual learning performance
Time Frame: Through study completion, an average of 2 months per participant
Discrimination performance (in percentage) for auditory delayed-matching to sample task
Through study completion, an average of 2 months per participant
Behavioral sensory profile
Time Frame: Through study completion, an average of 2 months per participant
Score (in absolute score) for psychomotor evaluation (Échelle des Particularités Sensori-psychomotrices dans l'Autisme)
Through study completion, an average of 2 months per participant
Sensory profile questionnaire
Time Frame: Through study completion, an average of 2 months per participant
Score (in absolute score) for sensory questionnaire (Dunn Sensory Profile)
Through study completion, an average of 2 months per participant
Cognitive psychological profile
Time Frame: Through study completion, an average of 2 months per participant
Score (in absolute score) for cognitive test (Raven's Progressive Matrices)
Through study completion, an average of 2 months per participant
Executive functions questionnaire
Time Frame: Through study completion, an average of 2 months per participant
Score (in absolute score) for executive functions questionnaire (BRIEF or BRIEF-A depending on the group)
Through study completion, an average of 2 months per participant
Attentional functions questionnaire
Time Frame: Through study completion, an average of 2 months per participant
Score (in absolute score) for attentional functions questionnaire (SNAP-IV-26 or ASRS-V1.1 depending on the group)
Through study completion, an average of 2 months per participant
Socio-emotional questionnaire
Time Frame: Through study completion, an average of 2 months per participant
Score (in absolute score) for socio-emotional questionnaire (AQ)
Through study completion, an average of 2 months per participant
Linguistic profile
Time Frame: Through study completion, an average of 2 months per participant
Score (in absolute score) for non-words and sentences repetition (LITMUS)
Through study completion, an average of 2 months per participant
Heart beat response to sensory stimulations
Time Frame: Through study completion, an average of 2 months per participant
Heart beat variation (in milliseconds) following sensory stimulation, recorded simultaneously with EEG
Through study completion, an average of 2 months per participant
Electrodermal activity response to sensory stimulations
Time Frame: Through study completion, an average of 2 months per participant
Electrodermal activity variation (in microsiemens) following sensory stimulation, recorded simultaneously with EEG
Through study completion, an average of 2 months per participant
Pupillary response to sensory stimulations
Time Frame: Through study completion, an average of 2 months per participant
Pupillary diameter variation (in millimeter) following sensory stimulation,recorded simultaneously with EEG
Through study completion, an average of 2 months per participant

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 15, 2026

Primary Completion (Estimated)

May 15, 2026

Study Completion (Estimated)

April 15, 2028

Study Registration Dates

First Submitted

March 26, 2026

First Submitted That Met QC Criteria

April 17, 2026

First Posted (Actual)

April 21, 2026

Study Record Updates

Last Update Posted (Actual)

April 21, 2026

Last Update Submitted That Met QC Criteria

April 17, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • DR240270

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Neurodevelopmental Disorders

Subscribe